MedPath

New E-Service for a Dietary Approach to the Elderly

Early Phase 1
Completed
Conditions
Aged
Healthy
Interventions
Behavioral: Optimal Diet
Dietary Supplement: VSL#3®
Dietary Supplement: AISA-5203-L
Dietary Supplement: Argan oil
Registration Number
NCT01179789
Lead Sponsor
Charite University, Berlin, Germany
Brief Summary

Ageing of the population is a major event in the world. Gerontological/geriatric literature unanimously indicate that physical exercise and diet are at present the two available fundamental approaches to contrast/prevent most of the age associated alterations. In the elderly the inflammageing, the oxidative stress and the alteration of the intestinal microbiota can be influenced by nutritional status and possibly corrected by an appropriate dietetic intervention:

Nowadays the nutraceutical food supplements become an opportunity for the consumer to improve the quality of individual diet for specific needs

Detailed Description

Ageing of the population is a major event in the world. Gerontological/geriatric literature unanimously indicate that physical exercise and diet are at present the two available fundamental approaches to contrast/prevent most of the age associated alterations. In the elderly the inflammageing, the oxidative stress and the alteration of the intestinal microbiota can be influenced by nutritional status and possibly corrected by an appropriate dietetic intervention:

Nowadays the nutraceutical food supplements become an opportunity for the consumer to improve the quality of individual diet for specific needs

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
48
Inclusion Criteria
  • Age: from 65 to 85 years
  • Body Mass Index: 22-30 kg/m2
  • ECOG Performance status: WHO performance score 0 to 2
  • Absence of known diseases and/or abnormalities of haematological parameters (haematological, inflammatory, metabolic, hepatic and renal diseases)
  • The subjects must be able to comply with management of nutraceutical products and with scheduled follow-up
  • The subjects must be able to use the computer and to access to the web, by themselves or with the help of a caregiver
Exclusion Criteria
  • History of significant neurologic or psychiatric disorders including dementia, seizures, bipolar disorder
  • Geriatric anorexia [less than 2 full meals per day and /or less than one serving of dairy products (milk, cheese, yogurt) per day or two or more servings of legumes or eggs per week or one serving of meat, fish or poultry every day]
  • Weight loss > 5% in the last month
  • Previous antibiotic treatment within 4 months
  • Active infection requiring per OS or IV antibiotics, including active tuberculosis, known and declared HIV, HCV
  • Constipation and/or abdominal pain/discomfort that require dietary supplements or medical therapy
  • Gastric disease that requires medical therapy (e.g. gastric secretion inhibitory drugs)
  • Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis, diverticulosis, diverticulitis)
  • Diabetes mellitus
  • Dislipidemia and/or any metabolic disease that requires medical or dietetic treatment
  • Myocardial infarction within 6 months prior to study entry, congestive heart disease, uncontrolled cardiac insufficiency, and any current grade 3 or 4 cardio-vascular disorder despite treatment
  • Current history of neoplasm except for curatively treated non melanoma skin cancer or in situ carcinoma of the cervix and except for other cancer curatively treated and with no evidence of disease for at least 5 years
  • Other sever underlying medical conditions, which could impair the ability of the patient to participate in the study
  • Chronic anti-inflammatory therapy with FANS or previous therapy within 20 days from the beginning of the study. The occasional use of anti-inflammatory therapy is not an exclusion criteria, but the use is not allowed within 3 days before the analysis and for more than 8 days/2 months during the study
  • Previous (within 15 days) or concomitant treatment that modifies intestinal absorption (e.g. metformin, acarbose in diabetic treatment...)
  • Probiotics, prebiotics or symbiotics (yogurt or another functional foods) intake in the last 3 weeks
  • Use of food supplements or functional foods such as probiotics, prebiotics, symbiotics, vitamins and minerals different than whose established in this study, is not allowed during the study period or previously within 1 week (except for vitamin D, calcium, vitamin B12)
  • Total parenteral nutrition within 4 months
  • History of allergy to one of the excipients present in the products under evaluation
  • Concomitant or within 4 week period administration of any experimental drug, food supplements or nutraceuticals under investigation
  • Subjects clearly intending to withdraw from the study if not randomised in a given arm, or subjects who cannot be regularly followed up for psychological, social, familial or geographic reasons
  • Subjects with expected non-compliance to protocol guidelines

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Optimal DietOptimal DietDiet advices will receive the Optimal Diet for Elderly
VSL#3VSL#3®Diet advices + VSL-3: will receive the Optimal Diet for Elderly + VSL#3® probiotic blend
AISA-5203-LAISA-5203-LDiet advices + 5203-L: will receive the Optimal Diet for Elderly + AISA-5203-L fruit extracted terpene
Argan oilArgan oilDiet advices + Argan oil: will receive the Optimal Diet for Elderly + Argan
Primary Outcome Measures
NameTimeMethod
High-sensitivity C-reactive protein (hs-CRP) as measure of systemic low-grade inflammation (cardiovascular risk)2 months
Secondary Outcome Measures
NameTimeMethod
Inflammageing status as measure of ageing-associated inflammatory processes2 months

WBC, hemoglobin, erythrocyte sedimentation rate, fibrinogen, total cholesterol, triglycerides, insulin, glucose, IL-6, TNFα, IL-10, TGF-1, IGF-1, adiponectin, leptin, homocysteine, folic acid and vitamin B12

Oxidative stress2 months

Plasma total antioxidant capacity by TEAA (Trolox Equivalent Antioxidant Activity), glutathione , superoxide dismutase, glutathione peroxidase, glutathione reductase, catalase activities

Gut micobiota2 months

Expression of 16S ribosomal RNA bacterial groups from feces by RT-PCR. Ratio between lactobacilli and clostridia bacteria as measure of impact of personalized nutrition with and without nutraceuticals on gut microbiota.

Quality of life (QoL)2 months

Daily visual analogue scale, SF-36 and General Health Questionnaire (GHQ) as direct measures of QoL. ECOG performance status, IADL, Spielberger Anxiety Index (SAI), and CED-D scale as indirect measures of quality of life.

Physical performance status2 months

Short physical performance battery (SBBP), muscle function (hand-grip dynamometry, and physical activity level (IPAQ).

Compliance2 months

Daily visual analogue scales as measures of compliance to web diet advices and to the nutraceutical intake.

Trial Locations

Locations (1)

Charité - Universitätsmedizin Berlin

🇩🇪

Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath